|Bid||816.56 x 800|
|Ask||822.00 x 800|
|Day's Range||808.90 - 833.28|
|52 Week Range||668.00 - 847.50|
|Beta (5Y Monthly)||0.19|
|PE Ratio (TTM)||21.64|
|Earnings Date||Nov 02, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||907.48|
Subscribe to Yahoo Finance Plus to view Fair Value for REGN
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Companies generally decide to engage in stock splits after their shares have soared to a level that may put them out of reach for many retail investors. A stock split doesn't change the real market value of a company, nor does it alter the value of any investor's holdings, but it does bring down the price of each individual share. Of course, it's impossible to predict which company may perform a stock split with 100% accuracy, but a top performer that has been setting new share price highs could make a good candidate.
If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two most common subtypes of non-Hodgkin lymphoma European Medicines Agency also reviewing odronextamab Marketing Authorization Application TARRYTOWN, N.Y., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for odronextam